Glenn Dale

New Capabilities

Overseeing BV100 clinical program

No genuinely new class of antibiotic has reached patients since 1987. In the nearly four decades since, bacteria have steadily evolved resistance to existing drugs, and carbapenem-resistant Acinetobacter baumannii—a hospital-acquired pathogen that kills up to 60 percent of ventilated pneumonia patients—now sits atop the World Health Organization's list of critical-priority threats. On March 16, 2026, Swiss biotech BioVersys received clearance from the United States Food and Drug Administration (FDA) to begin enrolling American patients in a Phase 3 pivotal trial of BV100, a drug that cut 28-day mortality in half during earlier testing.

Updated Yesterday